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ABSTRACT 
Targeted gene delivery to the brain is a critical tool for neuroscience research and has significant potential to treat human disease. However, 
the site-specific delivery of common gene vectors such as adeno-associated viruses (AAVs) is typically performed via invasive injections, 
limiting their scope of research and clinical applications. Alternatively, focused ultrasound blood-brain-barrier opening (FUS-BBBO), 
performed noninvasively, enables the site-specific entry of AAVs into the brain from systemic circulation. However, when used in 
conjunction with natural AAV serotypes, this approach has limited transduction efficiency, requires ultrasound parameters close to tissue 
damage limits, and results in undesirable transduction of peripheral organs. Here, we use high throughput in vivo selection to engineer 
new AAV vectors specifically designed for local neuronal transduction at the site of FUS-BBBO. The resulting vectors substantially enhance 
ultrasound-targeted gene delivery and neuronal tropism while reducing peripheral transduction, providing a more than ten-fold 
improvement in targeting specificity. In addition to enhancing the only known approach to noninvasively target gene delivery to specific 
brain regions, these results establish the ability of AAV vectors to be evolved for specific physical delivery mechanisms.  
INTRODUCTION 
 
Gene therapy is one of the most promising emerging approaches to 
treating human disease. Recently, a number of gene therapies were 
approved for clinical use, including blindness1, muscular dystrophy2, 
and metabolic disorders3. Many of these therapies use adeno-
associated viral vectors (AAVs) to deliver genes to various organs, 
but few target the brain. Although several neurological and 
psychiatric diseases could benefit from gene therapies targeting 
specific neural circuits, a key challenge limiting the development of 
such treatments is the need for invasive intracranial injections of the 
viral vectors. While recent advances are enabling brain-wide gene 
delivery from systemic4-6 or cerebrospinal fluid circulation7, these 
approaches do not provide the spatial targeting needed to address 
regionally defined neural circuits. 
Focused ultrasound blood-brain barrier opening (FUS-
BBBO) is a recently developed technique with the potential to 
overcome these limitations by providing a route to noninvasive, site-
specific gene delivery to the brain8-12. In FUS-BBBO ultrasound is 
focused through an intact skull13, 14 to transiently loosen tight 
junctions in the BBB and allow for the passage of AAVs from the 
blood into the targeted brain site. FUS-BBBO can target 
intravenously administered AAVs to millimeter-sized brain sites or 
cover large regions of the brain without tissue damage. These 
capabilities place FUS-BBBO in contrast with intracerebral 
injections, which are invasive and deliver genes to a single 2-3 
millimeter-sized region per injection15, 16, requiring a large number of 
brain penetrations to cover larger regions of interest. At the same 
time, the spatial targeting capability of FUS-BBBO differentiates it 
from the use of spontaneously brain-penetrating engineered AAV 
serotypes, which lack spatial specificity5. In proof of concept studies, 
FUS-BBBO has been used in rodents to introduce AAVs encoding 
reporter genes such as GFP8, 9, growth factors17, optogenetic 
receptors10. The delivery of chemogenetic receptors to the 
hippocampus provided the ability to modulate memory formation11. 
Despite its promise, three critical drawbacks currently limit the 
potential of FUS-BBBO in research and therapy applications. First, 
while the BBB effectively prevents non-FUS-targeted regions of the 
brain from transduction by systemically administered AAV, 
peripheral organs have endothelia that allow AAV entry and 
consequently receive a high dose of the virus, which could lead to 
toxicity18. Second, the relative inefficiency of AAV entry at the site 
of FUS-BBBO leads to the requirement of high doses of systemic 
AAVs, on the order of ~1010 viral particles per gram of body weight. 
While this magnitude has been used in recent clinical trials, it drives 
higher peripheral transduction and adds to the cost of potential 
therapies. Third, efficient delivery of AAV typically require acoustic 
parameters below, but close to9, 19, the threshold for brain tissue 
damage, reducing the margin for error in interventional planning. 
We reasoned that these limitations arise from the fact that wild-type 
serotypes of AAV did not evolve to cross physically loosened 
biophysical barriers and are therefore not optimal for this purpose. 
We hypothesized that we could address these limitations by 
developing new engineered viral serotypes specifically optimized for 
FUS-BBBO delivery. Capsid engineering techniques20 in which 
mutations are introduced into viral capsid proteins have been used 
to enhance gene delivery properties such as tissue specificity5, 6, 21-23, 
immune evasion24, or axonal tracing25. However, they have not yet 
been used to optimize viral vectors to work in conjunction with 
specific physical delivery mechanisms. 
To test our hypothesis, we performed in vivo selection of 
mutagenized AAVs in mice in conjunction with FUS-BBBO (Fig. 
1) by adapting a recently developed Cre-recombinase-based 
screening methodology6, 23. We identified 5 viral capsid mutants with 
enhanced transduction at the site of FUS-BBBO and but not in the 
untargeted brain regions. We then performed detailed validation 
experiments comparing each of these mutants to the parent wild-
type AAV, revealing a significant increase in on-target transduction 
efficiency, increased neuronal tropism, and a marked decrease in 
off-target transduction in peripheral organs, resulting in an overall 
performance improvement of more than 10-fold. These results 
demonstrate the evolvability of AAVs for specific physical delivery 
methods.
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Results 
 
High-throughput in vivo screening for AAVs with efficient FUS-
BBBO transduction 
To identify new AAV variants with improved FUS-
BBBO-targeted transduction of neurons, we generated a library of 
viral capsid sequences containing insertions of 7 randomized amino 
acids between residues 588 and 589 of the AAV9 capsid protein 
(Supplementary Fig. S1). AAV9 was chosen as a starting point due 
to its use in previous FUS-BBBO studies8, 9, 11. Meanwhile, 7-mer 
insertions have been widely used to engineer AAVs with new 
properties5, 6, 20-25.  
To make the screening more efficient, we employed 
recombination-based AAV selection6, 23. In this approach, each viral 
vector genome in the library encodes a mutated capsid protein 
alongside another segment of DNA that gets inverted in the 
presence of Cre recombinase (Supplementary Fig. S1a). Screening 
in Cre-expressing cells then allows the identification of capsid 
variants with the confirmed ability to transduce the cells, with the 
successful capsid sequences amplified by PCR using inversion-
specific primers (Supplementary Fig S1b). Using this approach, in 
vivo selection in mice expressing Cre recombinase under neuron-
specific promoters ensures the recovery of neuron-transducing 
AAV variants5, 6, 26. 
To screen specifically for mutants with enhanced 
transduction at the site of FUS-BBBO, we followed a two-step 
strategy (Fig. 1a, b). We first down-selected our 1.3 x 109-capsid 
library to a smaller number of variants that were capable of entering 
the brain at the site of FUS-BBBO, and then re-screened these 
variants to quantify enhancement and FUS-target specificity of FUS-
BBBO-mediated transduction. We employed FUS parameters 
below tissue damage limits11, 27 (0.33 MPa at 1.5 MHz, 10 ms pulse 
length, 1 Hz repetition frequency, 0.22 ml dose of microbubbles 
per gram of body weight). We injected an AAV library 
intravenously (IV) and immediately after applied FUS to the brains 
of two hSyn1-CRE mice to open the BBB, using magnetic 
resonance imaging (MRI) guidance for anatomical targeting, and 
confirming the opening with contrast-enhanced MRI. We targeted 
4 sites within one hemisphere (Fig. 2a). Our library contained a total 
of 1.3 x 109 clones, at a dose of 6.7x109 viral particles per gram of 
body weight. After 2 weeks we euthanized the mice and collected 
their brains. Immediately after, we extracted the viral DNA from 
the brain and used Cre-dependent PCR amplification to recover 
and selectively amplify the viral DNA from AAV particles that 
transduced neurons. We then performed next-generation 
sequencing (NGS) of the capsid region and selected the 2,098 most 
abundant sequences for subsequent evaluation. Based on the design 
of this screen, each of these variants was pre-selected to able to enter 
the brain at the site of FUS-BBBO and transduce neurons. 
However, the specificity of FUS-mediated entry and efficiency of 
transduction by these variants could not be determined 
quantitatively at this stage due to the small copy number of each 
variant in the library. 
Figure 1. Screening methodology for generation of an AAV for improved site-specific noninvasive gene delivery to the brain. a, 
Summary of the high-throughput screening and selection process. AAV library is administered intravenously (I.V.) and delivered to one brain 
hemisphere through FUS-BBBO. After 14 days mice are euthanized, their brain harvested, and the DNA from selected hemispheres is extracted. The 
DNA is then amplified by Cre-dependent PCR that enriches the viral DNA modified by Cre. In our case, neurons expressed Cre exclusively, and the 
Cre-dependent PCR enriched viral DNA of AAVs that transduced neurons. We subjected the obtained viral DNA to next-generation sequencing for 
the targeted hemisphere (round 1) or both targeted and control hemispheres (round 2). The process is then repeated for the next round (steps exclusive 
to round 2 indicated by the grey text). b, Overall, 1.3 billion clones were screened in the first round, and 2098 clones in the second round of selection. 
Out of these clones, we selected 5 that were tested in low-throughput to yield AAV.FUS.3 – a vector with enhanced FUS-BBBO gene delivery. 
 
Figure 2. High throughput screening yields vectors with 
improved FUS-BBBO gene delivery. a, An MRI image showing 
mouse brain with 4 sites opened with FUS-BBBO in one hemisphere. The 
bright areas (arrowheads) indicate successful BBB opening and 
extravasation of the MRI contrast agent Prohance into the brain. This 
BBB opening was used for delivery of the AAV library. b, Sequencing 
results of round 2 of screening show a fraction of NGS reads within the 
DNA extracted from brains of Syn1-Cre mice subjected to FUS-BBBO 
and injected with a focused library of 2098 clones. Each dot represents a 
unique capsid protein sequence, and the position on each axis corresponds 
to the number of times the sequence was detected in the FUS-targeted 
and untargeted hemispheres. Markers below the dotted line represent 
sequences that on average showed 100-fold higher enrichment in the 
targeted hemisphere as compared to the control hemisphere. Dark grey 
dots represent 35 clones that are enriched in the FUS targeted 
hemispheres at least 100-fold in every tested mouse and DNA sequence 
encoding the 7-mer insertion peptide. Yellow dots represent 5 clones 
(AAV.FUS.1-5) selected for low-throughput testing. Due to the use of a 
logarithmic plot, clones that had zero copies detected in either of the 
hemispheres are not shown. 
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To quantitatively compare our 2,098 down-selected capsid variants, 
we re-synthesized and packaged them as a new AAV library at a 
dose of 1.3 x 109 viral particles per gram of body weight, 
corresponding to ~1.5-3x107 viral particles of each clone being 
injected into each mouse. In each of two hSyn-CRE mice, we 
injected an AAV library intravenously and opened the BBB in one 
hemisphere using MRI-guided FUS as in round 1. After 2 weeks, 
the brains were extracted, hemispheres separated and the DNA 
from FUS-targeted and untargeted hemispheres extracted for each 
mouse. The DNA extract was amplified by the CRE-dependent 
PCR to enrich for viral genomes that transduced neurons. After 
FUS-BBBO delivery, DNA extraction, CRE-dependent PCR, and 
NGS, we recovered 1,433 sequences.  
To identify the most improved candidates we examined 
their copy number in the targeted hemispheres and compared it to 
the untargeted hemispheres (Fig. 2b). We first looked for variants 
that were at least 100-fold more represented in the targeted 
hemisphere relative to the untargeted hemisphere to identify AAVs 
that selectively transduced sites subjected to FUS-BBBO. From this 
list, we further selected candidates for which the 100-fold difference 
was maintained in both mice and in each alternative codon 
sequence corresponding to its 7-mer peptide, thus ensuring 
robustness of the NGS data. In the end, 35 sequences met these 
criteria (dark grey symbols in Fig. 2b). Among these FUS-BBBO-
specific variants, we chose the 5 most frequently detected 
sequences, which we hypothesized would code for AAV capsids 
with the most efficient neuronal transduction. We re-synthesized 
these sequences, cloned them into the AAV9 capsid between amino 
acids 587-588, and packaged them for detailed evaluation, naming 
them AAV.FUS 1 through 5. 
 
AAV.FUS candidates show enhanced transduction of neurons in 
targeted brain regions and reduced transduction of peripheral 
organs 
 
An ideal AAV vector for ultrasound-mediated gene 
delivery to the brain would efficiently transduce targeted neurons 
while avoiding peripheral tissues, such as the typically highly 
transduced liver28. Additionally, such a vector should only transduce 
the brain at the FUS-targeted sites. Of the natural AAV serotypes, 
AAV9 is most commonly used in FUS-BBBO because it 
transduces neurons at the ultrasound target with relatively high 
specificity compared to untargeted brain regions8, 10, 11. However, 
AAV9 requires high doses to achieve significant gene expression 
and transduces peripheral tissues in the process8, 10, 11, leaving 
substantial room for improvement. We decided to test our five 
selected AAV.FUS vectors against AAV9. 
Figure 3. AAV.FUS candidates improve efficiency of gene delivery to the brain and reduce peripheral transduction. a, Representative 
images were obtained from mice co-injected with AAV9 and a AAV.FUS.3 at 1010 viral particles per gram of body weight. After 3 weeks, the mice were 
perfused, brains were extracted and then sectioned at 50 microns. Sections were imaged on a confocal microscope with 20x objective showing brain 
transduction by AAV9 (red) and AAV.FUS.3 (green), and counterstained with a neuronal stain (NeuN, blue). b, All but one (AAV.FUS.4) AAV.FUS 
candidates showed significant improvement over the co-injected AAV9. c, We found that few cells were transduced outside of the FUS-targeted site 
and AAV.FUS.3 and AAV9 were not significantly different (0.19% off target transduction for AAV.FUS.3 vs 0.4% for AAV9; p=0.072, two way Anova 
with Sidak multiple comparisons test). Similarly other candidates also showed no differences (AAV.FUS.1, p=0.99 n=6; AAV.FUS.2, p=0.98, n=5; 
AAV.FUS.4, p=0.86, n=6; AAV.FUS.5, p=0.83, n=6). d, Representative images showing liver transduction by AAV9 (red) and AAV.FUS.3 (green). 
e, All tested candidates showed reduction of the liver transduction as compared to the co-injected AAV9 in the same mice for which brain expression 
was analyzed. f, We defined the fold-improvement in targeting efficiency as the ratio of brain transduction to the liver transduction efficiency using 
AAV9 as a baseline, which suggested that AAV.FUS.3 is the top candidate for further study. Scale bars are 50 microns in panels a, c, unless otherwise 
noted. (**** = p<0.0001; *** = p<0.001; ** = p <0.01; * = p<0.05, ns = not significant); Error bars are 95% CI. 
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We performed FUS-BBBO while intravenously co-
administering each AAV.FUS candidate alongside AAV9 in 
individual comparison experiments. Consequently, each mouse 
had an internal control where the location and extent of FUS-
BBBO was identical for both serotypes. To quantify the 
transduction efficiency, we encoded the fluorescent proteins 
mCherry and EGFP in AAV9 and each AAV.FUS variant, 
respectively, under a general CaG promoter. After 2 weeks of 
expression, we counted the numbers of mCherry and EGFP-
expressing cells within the site of FUS-BBBO. The reliability of this 
quantification method was established by comparing cell counts for 
co-administered AAV9-EGFP and AAV9-mCherry 
(Supplementary Fig. S2). Our quantification showed that 
AAV.FUS.1, 2, 3, and 5 had significantly improved transduction 
efficiency compared to AAV9 (p = 0.0274, 0.0003, 0.0052, 0.0087, 
respectively, Fig. 3, a-b) wherease AAV.FUS.4 showed no 
improvement (p = 0.2556). The fold-change in transduction relative 
to AAV9 was greatest for AAV.FUS.2, and lowest for AAV.FUS.4 
(Supplementary Fig. S3). None of the AAV.FUS candidates 
produced off-target expression within the brain (Fig. 3c). 
Next, we evaluated the extent to which AAV.FUS 
candidates transduce off-target peripheral organs. In mice that 
received intravenous co-injections of AAV9-mCherry and each 
variant of AAV.FUS-EGFP we counted transduced cells in the liver, 
a peripheral organ known to be targeted by AAVs and a potential 
source of dose-limiting toxicity29, 30. Two weeks after injection, we 
collected liver tissues and imaged the livers, counting cells 
expressing each fluorophore (Fig. 3, d-e). We found markedly 
reduced liver transduction among the AAV.FUS candidates 
compared to AAV9 (Fig 3 e). AAV.FUS 3 showed the largest 
reduction in liver transduction compared to the wild-type serotype 
(6.8-fold reduction, p<0.0001), which was significantly higher 
reduction compared to the other tested AAV.FUS candidates 
(Supplementary Fig. S4). 
Our analyses of brain and liver transduction showed that 
AAV.FUS candidates both decrease the targeting of the peripheral 
tissue and increase the transduction efficiency of the targeted brain 
regions, which leads to a large overall improvement in transduction 
specificity, expressed as the ratio of the fold-increase in brain 
transduction and the fold-decrease in liver transduction compared 
to AAV9. By this metric, AAV.FUS.3 showed a 12.1-fold 
improvement, significantly greater than the other candidates 
(p<0.0001 for all pairwise comparisons, one-way ANOVA with 
Tukey-HSD post hoc test; Fig. 3f).  
A final criterion for successful gene delivery in many 
applications is the ability to transduce specific cell-types at the 
targeted anatomical location, for example neurons. AAV9 
transduces both neuronal and non-neuronal cell types31-33. We 
hypothesized that, since our Cre-dependent screen used mice with 
the recombinase expressed under a neuronal promoter, our 
engineered variants could have a higher neuronal tropism relative 
to their wild-type parent serotype. To test this hypothesis, we 
immunostained brain sections from mice co-transduced with 
AAV9-mCherry and each variant of AAV.FUS-EGFP during FUS-
BBBO for the neuronal marker NeuN and imaged these sections 
for GFP, mCherry, and NeuN signal. The fraction of  
AAV9-transduced (mCherry-positive) cells that were also positive 
for NeuN was 44.7% (±0.75%, SEM; n=8). In contrast, all 
AAV.FUS candidates had higher neuronal tropism (Fig. 4), with 
neurons constituting between 64.6 (±0.97%, SEM) (AAV.FUS.1) 
and 69.8 (±1.8%, SEM) (AAV.FUS.3) of all transduced cells (one-
way ANOVA with Tukey-HSD post hoc test; p<0.0001 for all 
AAV.FUS candidates). These results show that in addition to 
improved specificity for targeted regions of the brain, the 
engineered viral capsids are more selective for neurons over other 
cephalic cell types.  
 
Region-specific transduction efficiency of AAV.FUS.3 
Based on its leading combination of neuronal tropism and 
improvement in brain specificity among the engineered variants, we 
selected AAV.FUS.3 for further evaluation as a FUS-BBBO-
specific viral vector. To further characterize its performance relative 
to AAV9, we decided to evaluate the efficiency of delivery when 
these vectors are targeted to different brain regions. To ensure that 
each region is targeted exclusively, only one brain region was 
targeted with FUS-BBBO in each tested mouse. To ensure the rigor 
of this investigation and account for variability in virus titration34, we 
obtained a new batch of both AAV9 and AAV.FUS.3 and tittered 
them independently. We evaluated the efficiency of transduction 
when these vectors were targeted by FUS-BBBO to the striatum 
(caudate putamen), thalamus, hippocampus, and midbrain of 
AAV.FUS.3. 
Figure 4. AAV.FUS candidates show improved neuronal tropism. a, All AAV.FUS candidates show improved neuronal tropism (p<0.0001). 
Upon FUS-BBBO gene delivery, AAV.FUS.3. has 56% more likelihood of transducing a neuron than AAV9 (69.8%, vs 44.9% neuronal transduction, 
respectively; p<0.0001).  b, Representative images showing AAV9 transducing both neurons (blue, NeuN staining, example neuron designated by an 
arrow) and non-neuronal cells (example non-neuronal cell designated by an arrowhead), c, In comparison, more of the cells transduced with AAV.FUS 
(green) are neurons (example neuron designated by an arrow), rather than non-neuronal cells (example cell designated by an arrowhead). Scale bars 
are 50 microns. (All p-values - **** = p<0.0001). Error bars are 95% CI. 
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As in our earlier experiments, we observed a major improvement 
in AAV.FUS.3 transduction compared to AAV9 in all targeted 
regions, with a fold-change ranging from 2.4±0.08 to 4.3±0.08 (95% 
CI, Fig. 5). Among brain regions, we found that the hippocampus 
(Hpc) is transduced with a particularly elevated relative efficiency, 
while the cortex (Ctx) showed the lowest, but still substantial, 
improvement. These results indicate that AAV.FUS.3 can target 
multiple brain regions with improved efficiency, while suggesting 
the potential for further engineering AAVs with region-enhanced 
tropism in FUS-BBBO delivery. 
DISCUSSION 
Our results show that viral vectors can be engineered to improve 
noninvasive, site-specific gene delivery to the brain using 
ultrasound-mediated blood-brain barrier opening. Gene therapy is 
widely used in research and is becoming a clinical reality. However, 
most of the available methods for gene delivery to the brain either 
lack regional specificity or are invasive and challenging to apply to 
large brain regions4-7, 15, 16. While FUS-BBBO promises to overcome 
these challenges, its use in conjunction with AAVs encounters 
challenges of parameter safety and peripheral transduction35 which, 
despite longstanding effort, have not been fully solved through the 
optimization of ultrasound parameters8, 36, 37 and equipment38, 39 alone. 
Simply increasing the intravenous dose of natural AAVs is not 
feasible due to the additional cost of the virus production, stronger 
immune response to the virus40, higher non-specific transduction41-43 
of peripheral tissues and associated toxicity30, 44, 45.  
In this study, we approached the problem of improving FUS-
BBBO gene delivery by engineering the viral vectors themselves. 
The resulting improvements include an increase in brain 
transduction per virus injected, a reduction in peripheral expression 
and an increase in neuronal tropism. Among the selected 5 
AAV.FUS candidates, four transduced target brain sites more 
efficiently than AAV9 while also lowering transgene expression in 
the liver in the same mice. Our top candidate, which we call 
AAV.FUS.3, demonstrated improved transduction in five different 
brain regions and an overall efficiency of targeting the brain, defined 
as the ratio of brain to liver (peripheral) transduction, improved 
12.1-fold compared to AAV9. This improvement in tissue 
specificity is particularly important because peripheral transduction 
can lead to toxicity. For example, AAV-based gene therapy has 
been shown to induce liver toxicity in clinical trials29. 
Our results suggest the need to investigate the mechanisms 
by which AAVs enter the brain after FUS-BBBO and what accounts 
for the differences in efficiency among serotypes. The prevailing 
understanding of FUS-BBBO mechanisms suggests that FUS 
loosens tight junctions in the vasculature, allowing molecules and 
nanoparticles such as AAVs to pass from the blood into the brain46. 
Within this framework, reductions in peripheral uptake (leaving 
more AAV to circulate) and reduced binding to extracellular 
matrix47 could help certain serotypes enter through physically-
generated openings and reach neurons more efficiently. Another 
possibility is that FUS-BBBO could cause molecular changes to the 
vascular endothelium, leading to a more complex interaction 
between viral vectors and their target. Understanding these factors 
would enable additional future engineering and optimization of 
FUS-BBBO-based gene delivery. 
Overall, this study shows that the molecular engineering of 
AAV capsids can lead to improved ultrasound-mediated gene 
delivery to the brain. Our screen yielded AAV.FUS.3, the first viral 
vector expressly engineered to work in conjunction with a specific 
physical delivery method. 
 
MATERIALS AND METHODS 
 
Animals 
Animals. C57BL/6J and Syn-1-Cre mice were obtained from 
Jackson Lab. Animals were housed in a 12h light/dark cycle and 
were provided with water and food ad libitum. All experiments were 
conducted under a protocol approved by the Institutional Animal 
Care and Use Committee (IACUC) of the California Institute of 
Technology. 
 
Focused ultrasound equipment and BBB opening procedures 
FUS-BBBO. Adult male Syn1-Cre mice (at least 14 weeks old) were 
anesthetized with 2% isoflurane in air, the hair on their head 
removed with Nair depilation cream and then cannulated in the tail 
vein using a 30-gauge needle connected to PE10 tubing. The 
cannula was then flushed with 10 units (U)/ml of heparin in sterile 
saline (0.9% NaCl) and attached to the mouse tail using tissue glue 
(Gluture). Subsequently, the mice were placed in the custom-made 
plastic head mount and imaged in a 7T MRI (Bruker Biospec). A 
Figure 5. AAV.FUS.3 shows regional dependence of 
transduction efficiency. Hippocampus showed the highest, 4.3-fold, 
improvement in transduction over AAV9. a, Representative image 
comparing transduction of the cortex with AAV.FUS.3 (green) and AAV9 
(red). b, Representative image comparing transduction of the striatum 
with AAV.FUS.3 (green) and AAV9 (red). c, Representative image 
comparing transduction of the thalamus with AAV.FUS.3 (green) and 
AAV9 (red). d, Representative image comparing transduction of the 
hippocampus with AAV.FUS.3 (green) and AAV9 (red). e, Representative 
image comparing transduction of the midbrain with AAV.FUS.3 (green) 
and AAV9 (red). f, AAV.FUS.3 shows regional differences in transduction 
efficiency of the tested regions – cortext (ctx), striatum (Str), thalamus (Th), 
hippocampus (Hpc), midbrain (Mb). All differences were statistically 
significant (one way ANOVA, "F (4, 10) = 283.4", P<0.0001; All pairwise 
comparison p-values < 0.01, Tukey HSD post-hoc test). Scale bars are 50 
microns. Error bars are 95% CI. 
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fast low-angle shot sequence (echo time TE=3.9ms, repetition time 
TR=15ms, flip angle 20°) was used to record the position of the 
ultrasound transducer in relation to the mouse brain. Subsequently, 
the mice were injected via tail vein with AAVs. Immediately after 
viral injection, the mice were also injected with 1.5×106 DEFINITY 
microbubbles (Lantheus) and 0.125 µmol of ProHance (Bracco 
Imaging) dissolved in sterile saline, per g of body weight. The dose 
of DEFINITY was identical as used in our previous studies1. The 
dose of ProHance was chosen based on the manufacturer’s 
recommendations. Within 30 s, the mice were insonated using an 
eight-channel FUS system (Image Guided Therapy) driving an 
eight-element annular array transducer with a diameter of 25 mm 
and a natural focal point of 20 mm, coupled to the head via 
Aquasonic ultrasound gel. The gel was placed on the top and both 
sides of the animal’s head to minimize reverberations from 
tissue/air interfaces. The focal distance was adjusted electronically. 
The ultrasound parameters used were 1.5MHz, 1% duty cycle, and 
1Hz pulse repetition frequency for 120 pulses and were derived 
from a published protocol. The pressure was calibrated using a fiber 
optic hydrophone (Precision Acoustics), with 21 measurements and 
uncertainty of ±3.8% (SEM). The pressure for FUS-BBBO was 
chosen to maximize the safety of delivery and was chosen on the 
basis of our previous studies1 and preliminary data in our laboratory. 
The ultrasound parameters were 1.5MHz, 0.33 MPa pressure 
accounting for skull attenuation (18%)48, 1% duty cycle, and 1Hz 
pulse repetition frequency for 120 pulses. For each FUS site, 
DEFINITY and Prohance were re-injected before the additional 
insonation. Each animal underwent four insonations located in one 
hemisphere, starting from the midbrain and going forward. The 
time between each insonation was approximately 3 minutes and 
included 120 s of insonation and 1 minute for readjustment of 
positioning on the stereotaxic frame. The center focus of beams was 
separated by 1.35 – 1.5 mm (depending on mouse weight 25-35 g) 
in the anterior / posterior direction.  
 
Plasmids and DNA library generation 
The plasmids used were either obtained from Addgene, Caltech’s 
vector core, or modified from these plasmids. The AAV library 
genome used for selection (acceptor plasmid, rAAV9Rx/a-delta-
CAP) was obtained from Caltech’s vector core facility, as were other 
plasmids (REP2-CAP9Stop-DeltaX/A, pUC18). The Rep-Cap 
plasmid for packaging AAV.FUS candidates were modified from 
Addgene plasmid #103005 by introducing mutations selected from 
the screen. For testing the transduction we used a plasmid obtained 
from Addgene (pAAV-CaG-NLS-EGFP - #104061) and a plasmid 
modified in-house with exchanged EGFP for mCherry protein 
(pAAV-CaG-NLS-mCherry).  
Mutations were introduced into the acceptor plasmid using a PCR 




3’, targeted as a 7-aminoacid insertion between residues 587 and 
588. The amplified insert was then introduced into the capsid 
plasmid through restriction cloning using XbaI and AgeI enzymes. 
DNA from the treated brain was recovered by PCR using two pairs 
of plasmids – the first step of amplification was done using 5’-
CAGGTCTTCACGGACTCAGACTATCAG-3’ and 5’-
CAAGTAAAACCTCTACAAATGTGGTAAAATCG-3’ 
primers which selected for the DNA that has been modified by Cre 
enzyme. The second stage, intended to amplify the DNA was 
performed using a pair of primers:  5’-
ACTCATCGACCAATACTTGTACTATCTCTCTAGAAC-3’ 
and 5’- GGAAGTATTCCTTGGTTTTGAACCCAA 
-3’. 
 
Virus production and purification 
AAV library was purified as previously published6. In short, we 
transfected the DNA carrying a genome containing capsid which 
has been modified by the 7-mer insertion (10 ng per 100 mm 
diameter dish), the helper DNA containing REP protein (10 mg per 
100 mm diameter dish, and 9.99 mg of empty pUC19 carrier 
plasmid), and an AdV helper plasmid (20 mg per 100 mm diameter 
dish) using PEI. Media was changed 16 h after transfection, and 
then collected 48 h post-transfection and stored in 4C. 60h after the 
transfection, we scraped the cells into San digestion buffer (Tris pH 
8.5 with 500mM NaCl and 40 mM MgCl2 with Salt Active 
Nuclease). Virus in the media was precipitated using 1/5 volume of 
5X PEG8000+NaCl (40% PEG-8000 and 2.5M NaCl), incubated 
on ice for 2 h, and spun at 3000xg for 30min at 4C. The media and 
cell-scraped stocks were then combined and precipitated using 
iodixanol gradient precipitation (virus appears on the 40-60% 
iodixanol interface), diluted into 15 ml PBS with 0.001% Pluronic-
F68, and sterile-filtered through a 0.2-micron PES filter. Finally, the 
buffer was dialyzed using Amicon 100 KDa cut-off centrifuge filters 
at least 3 times to remove residual iodixanol, after which the virus 
was tittered using a standard qPCR protocol6. AAV.FUS candidates 
were packaged and titered using a commercial service (Vigene 
biosciences) to ensure reproducibility for external investigators, as 
the titers can show variability between different labs34. We have re-
titered the AAV.FUS.3 and AAV9 from another batch again in our 
lab, to make sure that the improvement of AAV.FUS over AAV9 
is consistent between investigators. 
 
In vivo selection and gene delivery 
To enable in vivo selection of AAV.FUS we delivered the AAV 
library to one hemisphere through FUS-BBBO. We targeted four 
sites corresponding to the striatum, dorsal hippocampus, ventral 
hippocampus, and midbrain using MRI guidance. We used 
0.33MPa pressure and other parameters as described in the 
Focused ultrasound equipment and BBB opening procedures 
section. The parameters used were identical during the in vivo 
selection and testing of the AAV.FUS candidates. The AAVs were 
delivered intravenously. For the first round of selection the dose 
delivered was 6.7E9 viral particles per gram of body weight. The 
library for the first round of evolution contained 1.3E9 sequences, 
yielding approximately 5 particles of each clone per gram of body 
weight. For the second round, where the library contained 2098 
candidates, 1.3E9 viral particles per gram of body weight were 
delivered, yielding 6.2E5 viral particles for each clone per gram of 
body weight. After FUS-BBBO mice were returned to the home 
cages for 14 days, after which they were euthanized by CO2 
overdose.  
 
Tissue preparation for DNA extraction 
The brains of mice euthanized with CO2 overdose were extracted, 
and the targeted hemisphere was separated from the control 
hemisphere with a clean blade. Each hemisphere was then frozen 
at -20C prior to DNA extraction. The brains were then 
homogenized in Trizol using a BeadBug tissue homogenization 
device with dedicated pre-filled 2.0 ml tubes with beads (Zirconium 
coated, 1.5 mm, Benchmark Scientific, Sayreville, New Jersey) for 
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1-3 minutes until tissue solution was homogenous. The DNA was 
then extracted with Trizol and amplified first with CRE-
independent, and then CRE-dependent PCR as previously 
published6. 
 
Next Generation Sequencing Data Analysis 
Next generation sequencing was performed using MiSeq (Illumina, 
San Diego, CA) using paired-end 75-base pair reads. The variable 
region of all detected capsid sequences was extracted from raw fastq 
files using the awk tool in Unix terminal. This process filtered out 
sequences not containing the constant 19bp region flanking each 
side of the variable region. Sequences were then sorted, checked 
for length, and ordered from highest to lowest copy number in the 
sequencing experiment. During the first screen, the top 3000 were 
chosen. Among these 3000, any sequence that was only a point 
mutation away from a sequence and 30x less abundant was removed 
and assumed to be a potential sequencing readout error. This led 
to our final library of 2098 sequences, which were synthesized by 
Twist Biosciences (San Francisco, CA) for use in the second round 
of screening. This second AAV library also included a set of 2098 
“codon-optimized” capsid variants that were encoded for the same 
protein as the original sequences but using a different DNA 
sequence chosen by the IDT codon optimization tool. To process 
the second batch of sequencing data, we first normalized the copy 
numbers of the sequences in each experiment to one to ensure 
comparability of different samples. Then, we filtered out sequences 
that were not contained within the input library. Finally, we 
evaluated the normalized frequency of reads for each sequence, 
defined as the normalized copy number of each sequence averaged 
among original and codon-optimized variants for each capsid. Top 
sequences for further analysis were selected to be the most 
abundant sequences that appeared at least 100x more frequently in 
the targeted brain hemisphere than the non-targeted hemisphere in 
all tested mice, and from these sequences, the top 5 were chosen as 
AAV.FUS candidates. 
 
Histology, and image processing 
After cardiac perfusion and extraction brains were post-
fixed for 24 h in neutral buffered formalin (NBF). Brains were then 
sectioned at 50-micron on Compresstome VF-300 (Precisionary 
Instruments, Natick, MA). Sections were immunostained with an 
anti-NeuN Alexa Fluor 405-conjugated antibody (RBFOX3/NeuN 
Antibody by Novus Biological, Littleton, CO, USA, stock number: 
NBP1-92693AF405). Sections were imaged on a Zeiss LSM-800 
microscope using a 20x objective. Channels’ laser intensities 
normalized to the brightness of mCherry and GFP proteins. Images 
were then randomized, anonymized, and exported as greyscale to 
ensure a lack of bias in color perception. The experimenter was 
blinded in terms of fluorophore color, tested AAV strain, or the 
mouse identification (H.L.). Three 100-micron sections of the brain 
were analyzed for each mouse, for each strain of the AAV including 
the section at the center of the FUS-target and the sections 500 and 
1000 microns anterior to that section.  The data was then 
independently validated by an experimenter blinded to the goals of 
the study (J.T). The inter-experimenter variability was 12.5% (1.9-
fold (RL, primary scorer) vs 2.1-fold difference (JT, secondary 
scorer), n=15 randomly selected images, a total of 11,230 cells 
counted) and the difference between the scores was not statistically 
significant (p=0.071, two-tailed, paired t-test). To evaluate the BBB 
permeability of the AAV in the absence of FUS-BBBO (off-target 
transduction), a randomly chosen untargeted region at least 2 mm 
from the center of targeted region (4 times the distance of distance 
half-width half maximum of pressure, resulting in ~16-fold pressure 
reduction) was used within the same sections that were used to 
evaluate transduction efficiency at FUS focus.  
 
Statistical analysis 
Two tailed t-test, without assuming equal variance, was 
used when comparing means of two data sets. For comparison of 
more than two data sets, one-way ANOVA was used, with a Tukey’s 
HSD post-hoc test to determine significance of pairwise 
comparisons. When more than one variable was compared across 
multiple samples, two-way ANOVA was used, followed by Sidak’s 
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